Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics of Thymoglobulin in Paediatric Haematopoietic Stem-cell Transplants

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* All patients who are scheduled to receive ATG 2.5mg/kg/day for 3 days as part of the preparative regimen for HSCT, as determined by the responsible HSCT physician.~* Written, informed consent~Exclusion Criteria:~* Hypersensitivity to rabbit proteins or to any product excipients~* Active acute or chronic infections, which would contraindicate any additional immunosuppression~* Known pregnancy or breastfeeding

- Gender: ALL
- Minimum Age: None
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Thymoglobulin (Type: EXPERIMENTAL): Thymoglobulin 7.5 mg/kg/course prior to HSCT

Based on this trial design, predict the completion outcome and termination type (if applicable).